- Home
- STG vs TCRX Comparison
STG vs TCRX Comparison
Compare STG & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- TCRX
- Stock Information
- Founded
- STG 2003
- TCRX 2018
- Country
- STG China
- TCRX United States
- Employees
- STG N/A
- TCRX N/A
- Industry
- STG Other Consumer Services
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- STG Real Estate
- TCRX Health Care
- Exchange
- STG Nasdaq
- TCRX Nasdaq
- Market Cap
- STG 73.4M
- TCRX 82.1M
- IPO Year
- STG 2018
- TCRX 2021
- Fundamental
- Price
- STG $7.16
- TCRX $1.83
- Analyst Decision
- STG
- TCRX Strong Buy
- Analyst Count
- STG 0
- TCRX 6
- Target Price
- STG N/A
- TCRX $9.50
- AVG Volume (30 Days)
- STG 6.4K
- TCRX 634.4K
- Earning Date
- STG 08-15-2025
- TCRX 08-11-2025
- Dividend Yield
- STG N/A
- TCRX N/A
- EPS Growth
- STG N/A
- TCRX N/A
- EPS
- STG 3.09
- TCRX N/A
- Revenue
- STG $269,356,990.00
- TCRX $4,421,000.00
- Revenue This Year
- STG N/A
- TCRX $159.20
- Revenue Next Year
- STG N/A
- TCRX N/A
- P/E Ratio
- STG $1.96
- TCRX N/A
- Revenue Growth
- STG N/A
- TCRX N/A
- 52 Week Low
- STG $4.25
- TCRX $1.02
- 52 Week High
- STG $11.06
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- STG 71.44
- TCRX 62.41
- Support Level
- STG $5.51
- TCRX $1.45
- Resistance Level
- STG $5.88
- TCRX $1.73
- Average True Range (ATR)
- STG 0.35
- TCRX 0.13
- MACD
- STG 0.10
- TCRX 0.02
- Stochastic Oscillator
- STG 67.32
- TCRX 94.05
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.